Evidence map›Paper›PMID 35978404›Full record

ArticleBMC medicine2022

The lipidomic profile of the tumoral periprostatic adipose tissue reveals alterations in tumor cell's metabolic crosstalk.

Antonio Altuna-Coy, Xavier Ruiz-Plazas, Silvia Sánchez-Martin, Helena Ascaso-Til, Manuel Prados-Saavedra, Marta Alves-Santiago, Xana Bernal-Escoté, José Segarra-Tomás, Matilde R Chacón

Open access · goldAbstract read
In one paragraph

Article in BMC medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Nutrients · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Antonio Altuna-Coy *Disease Biomarkers and Molecular Mechanisms Group, Institut d'Investigació Sanitària Pere Virgilii, Joan XXIII University Hospital, Universitat Rovira i Virgili, C/ Dr. Mallafré Guasch, 4. 43007, Tarragona, Spain.
Xavier Ruiz-Plazas *Disease Biomarkers and Molecular Mechanisms Group, Institut d'Investigació Sanitària Pere Virgilii, Joan XXIII University Hospital, Universitat Rovira i Virgili, C/ Dr. Mallafré Guasch, 4. 43007, Tarragona, Spain.
Silvia Sánchez-MartinDisease Biomarkers and Molecular Mechanisms Group, Institut d'Investigació Sanitària Pere Virgilii, Joan XXIII University Hospital, Universitat Rovira i Virgili, C/ Dr. Mallafré Guasch, 4. 43007, Tarragona, Spain.
Helena Ascaso-TilUrology Unit, Joan XXIII University Hospital, Tarragona, Spain.
Manuel Prados-SaavedraUrology Unit, Joan XXIII University Hospital, Tarragona, Spain.
Marta Alves-SantiagoDisease Biomarkers and Molecular Mechanisms Group, Institut d'Investigació Sanitària Pere Virgilii, Joan XXIII University Hospital, Universitat Rovira i Virgili, C/ Dr. Mallafré Guasch, 4. 43007, Tarragona, Spain.
Xana Bernal-EscotéPathology Unit, Joan XXIII University Hospital, Tarragona, Spain.
José Segarra-Tomás *Disease Biomarkers and Molecular Mechanisms Group, Institut d'Investigació Sanitària Pere Virgilii, Joan XXIII University Hospital, Universitat Rovira i Virgili, C/ Dr. Mallafré Guasch, 4. 43007, Tarragona, Spain. jsegarra.hj23.ics@gencat.cat.
Matilde R Chacón *Disease Biomarkers and Molecular Mechanisms Group, Institut d'Investigació Sanitària Pere Virgilii, Joan XXIII University Hospital, Universitat Rovira i Virgili, C/ Dr. Mallafré Guasch, 4. 43007, Tarragona, Spain. mrch2424@gmail.com.ORCID 0000-0003-1531-2165
Institut de Recerca Biomèdica Catalunya Sud · ESHospital Universitari Joan XXIII de Tarragona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPeriprostatic adipose tissue (PPAT) plays a role in prostate cancer (PCa) progression. PPAT lipidomic composition study may allow us to understand the tumor metabolic microenvironment and provide new stratification factors.

methodsWe used ultra-high-performance liquid chromatography-mass spectrometry-based non-targeted lipidomics to profile lipids in the PPAT of 40 patients with PCa (n = 20 with low-risk and n = 20 high-risk). Partial least squares-discriminant analysis (PLS-DA) and variable importance in projection (VIP) analysis were used to identify the most relevant features of PPAT between low- and high-risk PCa, and metabolite set enrichment analysis was used to detect disrupted metabolic pathways. Metabolic crosstalk between PPAT and PCa cell lines (PC-3 and LNCaP) was studied using ex vivo experiments. Lipid uptake and lipid accumulation were measured. Lipid metabolic-related genes (SREBP1, FASN, ACACA, LIPE, PPARG, CD36, PNPLA2, FABP4, CPT1A, FATP5, ADIPOQ), inflammatory markers (IL-6, IL-1B, TNFα), and tumor-related markers (ESRRA, MMP-9, TWIST1) were measured by RT-qPCR.

resultsSignificant differences in the content of 67 lipid species were identified in PPAT samples between high- and low-risk PCa. PLS-DA and VIP analyses revealed a discriminating lipidomic panel between low- and high-risk PCa, suggesting the occurrence of disordered lipid metabolism in patients related to PCa aggressiveness. Functional analysis revealed that alterations in fatty acid biosynthesis, linoleic acid metabolism, and β-oxidation of very long-chain fatty acids had the greatest impact in the PPAT lipidome. Gene analyses of PPAT samples demonstrated that the expression of genes associated with de novo fatty acid synthesis such as FASN and ACACA were significantly lower in PPAT from high-risk PCa than in low-risk counterparts. This was accompanied by the overexpression of inflammatory markers (IL-6, IL-1B, and TNFα). Co-culture of PPAT explants with PCa cell lines revealed a reduced gene expression of lipid metabolic-related genes (CD36, FASN, PPARG, and CPT1A), contrary to that observed in co-cultured PCa cell lines. This was followed by an increase in lipid uptake and lipid accumulation in PCa cells. Tumor-related genes were increased in co-cultured PCa cell lines.

conclusionsDisturbances in PPAT lipid metabolism of patients with high-risk PCa are associated with tumor cell metabolic changes.

Indexed as

LipidomicsTumor Necrosis Factor-alphaAdipose TissueBiomarkers, TumorFatty AcidsHumansInterleukin-6LipidsMalePPAR gammaBiomarkers, TumorFatty AcidsInterleukin-6LipidsPPAR gammaTumor Necrosis Factor-alphaDe novo fatty acid synthesisLipid metabolismLipidomicPeriprostatic adipose tissueProstate cancer

Identifiers

PMID35978404
PMCPMC9386931
OpenAlexW4292425715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.